Interleukin-2(Promet…oratories) Drug Due Diligence 2026

This Interleukin-2(Prometheus Laboratories) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

463

Registered trials

128

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Interleukin-2(Prometheus Laboratories) can convert its Interleukins profile and IL-2R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Interleukin-2(Prometheus Laboratories) (query alias: Interleukin-2(Prometheus Laboratories))
Modality / target	Interleukins; IL-2R; IL-2R agonists
Highest global status	Phase 2
Originator	Prometheus Laboratories, Inc.
Active developers	Prometheus Biosciences, Inc.

The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07700121	Early Phase 1	Not yet recruiting	10	Primary endpoint not disclosed in English source
NCT07681596	Phase 1/2	Recruiting	101	Primary endpoint not disclosed in English source
NCT07651618	Phase 2	Not yet recruiting	10	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma

Phase 1; n=6; evaluation: Not stated in English source. Reported fields: Number of Adverse Events = 3 Adverse Events (CTCAE v5.0) ; Number of Adverse Events = 1 Adverse Events (CTCAE v5.0)

A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase 1; n=36; evaluation: Not stated in English source. Reported fields: Other (Not Including Serious) Adverse Events = 0 Pts

651 Imneskibart, a human monoclonal antibody (mAb) that binds IL-2 and prevents CD25 binding, + low-dose subcutaneous IL-2: phase 2 update on CPI-refractory melanoma and non-small cell lung cancer (NSCLC) | Journal for ImmunoTherapy of Cancer

Phase 2; n=19; evaluation: Positive. Reported fields: SD = An acral melanoma patient progressed on anti-CTLA-4 and anti-PD-1 had 12 months stable disease (SD). In NSCLC, of two Cohort 2 patients, one is ongoing with SD at five months

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Interleukin-2(Prometheus Laboratories) addresses its disclosed development indications. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Interleukins—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 3 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-01-23	Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million	Approved	US$218.6M upfront; US$54.7M milestones
2018-07-17	CLINIGEN ACQUIRES GLOBAL RIGHTS TO PROLEUKIN® OUTSIDE THE UNITED STATES	Approved	US$120.0M upfront; US$30.0M milestones
2010-01-26	Prometheus Lab Announces Execution Of Commercialization Deal With Novartis	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO